Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | A session at EAN 2026 on advances in the management of non-inflammatory peripheral neuropathies

Nicolas Dubuisson • 27 Jun 2026
EAN 2026
Neuromuscular Disorders

Nicolas Dubuisson, MD, John Radcliffe University Hospital, Oxford, London & Cliniques Universitaires Saint-Luc, Brussels, Belgium, discusses recent advances in the management of non-inflammatory peripheral neuropathies. Dr Dubuisson shares the most impactful publications from 2025. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicolas Dubuisson

Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
1:55
Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
Nicolas Dubuisson • 27 Jun 2026
Neuromuscular disorder treatment updates at EAN 2024
1:00
Neuromuscular disorder treatment updates at EAN 2024
Nicolas Dubuisson • 2 Jul 2024
Diagnosing neuromuscular disorders: a case study of LGMD
1:57
Diagnosing neuromuscular disorders: a case study of LGMD
Nicolas Dubuisson • 2 Jul 2024
How to approach the classification of neuromuscular disorders
3:21
How to approach the classification of neuromuscular disorders
Nicolas Dubuisson • 2 Jul 2024

Related Videos

Findings from a Phase I trial of autologous SVF therapy in ALS
2:16
Findings from a Phase I trial of autologous SVF therapy in ALS
Zenglin Cai • 27 Jun 2026
Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
1:55
Improving the diagnosis of inflammatory myopathies: signals to facilitate early recognition
Nicolas Dubuisson • 27 Jun 2026
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
3:58
Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial
Richard Nowak • 24 Jun 2026
One big question with Richard Nowak: what MG advance could transform care in the next 3 years?
2:07
One big question with Richard Nowak: what MG advance could transform care in the next 3 years?
Richard Nowak • 28 Jun 2026
The content of VJNeurology is intended for healthcare professionals